August 19, 2013 7:56 am
![]()
ramosetron
19 August 2013
Irribow OD Tablet is a drug for treating IBS-D developed using WOWTAB which is one of the Astellas’ proprietary drug delivery technologies.
Singapore: Astellas Pharma has obtained the marketing approval of Irribow OD 1 Tablets 2.5µg / 5µg (generic name: ramosetron hydrochloride) in Japan. They were approved for an additional formulation of Irribow Tablets with the indication of diarrhea-predominant irritable bowel syndrome (IBS-D ) in male.
Read more at: http://www.biospectrumasia.com/biospectrum/news/193695/astellas-receives-approval-irribow-japan#.UhHORqI3CSo
Ramosetron (INN) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting.[1] Ramosetron is also indicated for a treatment of “diarrhea-predominant irritable bowel syndrome in males”.[2] In India it is marketed under the brand name of“IBset”.
It is only licensed for use in Japan and selected Southeast Asian countries. In Japan it is sold under the tradename Iribo (イリボー). [3] Elsewhere it is commonly sold under the tradename Nasea and in India as Nozia (300 mcg/ml Inj. & 100 mcg Tab.) [4]
Posted by DR ANTHONY MELVIN CRASTO Ph.D
Categories: Japan marketing, Japan pipeline
Tags: astellas, iribo, irribow, ramosetron
Mobile Site | Full Site
Get a free blog at WordPress.com Theme: WordPress Mobile Edition by Alex King.
Reblogged this on MedCheminAustralia.
LikeLike
By medchemnintabelle on August 20, 2013 at 10:43 am
Is this compound available in Latin America under some other brand name?
LikeLike
By joaquinbarroso on August 20, 2013 at 5:32 pm